Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Adenomas hipofisarios atípicos: experiencia de 10 años en un centro de referencia de Portugal

(2016) F. Tortosa et al.   NEUROLOGIA

Therapeutic innovations in endocrine diseases – part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas

(2016) Hélène Lasolle et al.   PRESSE MEDICALE

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide

(2015) Daniel Bengtsson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center

(2015) Filippo Ceccato et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas

(2015) Marco Losa et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment

(2015) Mariana Campderá et al.   Pituitary

Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina

(2015) Oscar D. Bruno et al.   International Journal of Endocrinology

A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

(2013) Jacqueline Trouillas et al.   ACTA NEUROPATHOLOGICA

Aggressive Silent GH Pituitary Tumor Resistant to Multiple Treatments, Including Temozolomide

(2013) Marie Batisse et al.   CANCER INVESTIGATION

DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

(2013) Toshio Hirohata et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment

(2012) Melanie Philippon et al.   ANNALES D ENDOCRINOLOGIE

Temozolomide and unusual indications: Review of literature

(2012) Zuzana Tatar et al.   CANCER TREATMENT REVIEWS

Temozolomide in the management of dopamine agonist-resistant prolactinomas

(2012) B. C. Whitelaw et al.   CLINICAL ENDOCRINOLOGY

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

(2012) Gérald Raverot et al.   CLINICAL ENDOCRINOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management

(2012) Ilyess Zemmoura et al.   Pituitary

New targeted therapies in pituitary carcinoma resistant to temozolomide

(2011) Emmanuel Jouanneau et al.   Pituitary

Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis

(2011) Ferdinand Roelfsema et al.   Pituitary

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

(2010) Marco Losa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS

(2009) Van Thang Cao et al.   NEUROSURGERY